search
Back to results

Cervical Cancer Screening in Madagascar Using Smartphone Photos and Mobile Telemedicine

Primary Purpose

Cervical Precancer

Status
Completed
Phase
Not Applicable
Locations
Madagascar
Study Type
Interventional
Intervention
D-VIA
Sponsored by
Prof. Patrick Petignat
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cervical Precancer focused on measuring cervical cancer, HPV, VIA, screening, smartphone, telemedicine

Eligibility Criteria

30 Years - 49 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • 30-49 years
  • HPV-positive
  • Attending the cervical cancer screening program conducted by the Saint-Damien Health-Care Centre
  • Understands study procedures and accepts voluntarily to participate by signing the informed consent form (ICF)

Exclusion Criteria:

  • Previous Hysterectomy
  • Conditions that can interfere with visualization of the cervix
  • Pregnancy > 20 weeks
  • Not able to comply with protocol study.

Sites / Locations

  • Saint-Damien Health-Care Centre

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

D-VIA

Arm Description

HPV high risk-positive (16, 18, 45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68) women had a cervical examination using acetic acid (VIA) application and visual inspection.

Outcomes

Primary Outcome Measures

Differences in sensitivity and specificity of VIA examination (control) and digital VIA to detect cervical cancer and pre-cancer
Sensitivity and specificity will be calculated using histological results as gold-standard. All lesion Cin2 and worse will be considered as pathological.

Secondary Outcome Measures

Overall agreement between diagnoses based on VIA examination (control) and diagnoses for the same patient based on digital VIA.

Full Information

First Posted
July 8, 2015
Last Updated
February 22, 2016
Sponsor
Prof. Patrick Petignat
search

1. Study Identification

Unique Protocol Identification Number
NCT02693379
Brief Title
Cervical Cancer Screening in Madagascar Using Smartphone Photos and Mobile Telemedicine
Official Title
Cervical Cancer Screening in Madagascar: Usability of Mobile Telemedicine for Detection of Precancerous Lesions From Smartphone Photos
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
February 2015 (undefined)
Primary Completion Date
September 2015 (Actual)
Study Completion Date
November 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Prof. Patrick Petignat

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether smartphone photos may assist health-care worker (on-site) and to evaluate the diagnostic reliability and accuracy of cervical examination with smartphone photos of VIA (D-VIA), on-site and off-site, compared with conventional VIA, for human papillomavirus (HPV) positive women.
Detailed Description
Background: Cervical cancer is the leading cause of cancer death in females in Madagascar. In this country, a large-scale screening of precancerous lesions with cytology is hardly possible, because of the lack of specialists and infrastructures. Visual inspection of the cervix with application of 5% acetic acid (VIA) is an inexpensive alternative but very subjective since it depends on the examiner's experience. Mobile telemedicine is a very promising tool in order to assist non-expert health-care workers in rural area for cervical cancer screening. Objective: To assess if Smartphone may assist health-care worker (on-site) and to evaluate the diagnostic reliability and accuracy of cervical examination with smartphone photos of VIA (D-VIA) compared with conventional VIA, for women testing positive for human papillomavirus (HPV). Material and method: On-site health care workers will be trained in VIA. Prescreened HPV-positive women will be referred to VIA evaluation, during which digital images with a smartphone (D-VIA) will be taken for later evaluation by a VIA specialist in Geneva linked by telemedicine. Women with positive VIA results will be treated with cold coagulation if eligible. Histological results will be considered as gold standard. The results will be analyzed with Cohen's kappa coefficient, Mcnemar's test and Bonferroni's adjustment for multiple comparisons to assess the performance of D-VIA. Expected results: Based on the results of this project, the investigators will develop an educational training and quality assurance program for health providers for VIA and so contribute to a scaling-up of cervical cancer control. An appropriate triage by VIA will reduce not only an excessive referral rate but also an excessive treatment delay, giving the possibility of a "screen (HPV), see (VIA/D-VIA), and treat" program in a single or two visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Precancer
Keywords
cervical cancer, HPV, VIA, screening, smartphone, telemedicine

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1041 (Actual)

8. Arms, Groups, and Interventions

Arm Title
D-VIA
Arm Type
Experimental
Arm Description
HPV high risk-positive (16, 18, 45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68) women had a cervical examination using acetic acid (VIA) application and visual inspection.
Intervention Type
Device
Intervention Name(s)
D-VIA
Intervention Description
D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared. Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment.
Primary Outcome Measure Information:
Title
Differences in sensitivity and specificity of VIA examination (control) and digital VIA to detect cervical cancer and pre-cancer
Description
Sensitivity and specificity will be calculated using histological results as gold-standard. All lesion Cin2 and worse will be considered as pathological.
Time Frame
up to 12 months
Secondary Outcome Measure Information:
Title
Overall agreement between diagnoses based on VIA examination (control) and diagnoses for the same patient based on digital VIA.
Time Frame
up to 12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 30-49 years HPV-positive Attending the cervical cancer screening program conducted by the Saint-Damien Health-Care Centre Understands study procedures and accepts voluntarily to participate by signing the informed consent form (ICF) Exclusion Criteria: Previous Hysterectomy Conditions that can interfere with visualization of the cervix Pregnancy > 20 weeks Not able to comply with protocol study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Petignat, Professor
Organizational Affiliation
Hôpitaux universitaires de Genève
Official's Role
Principal Investigator
Facility Information:
Facility Name
Saint-Damien Health-Care Centre
City
Ambanja
State/Province
Antsiranana
Country
Madagascar

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be used for scientific publications and congress presentations.
Citations:
PubMed Identifier
21351269
Citation
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
Results Reference
background
PubMed Identifier
21822676
Citation
Marquardt K. [Correlation of cervical cytology and histology]. Pathologe. 2011 Nov;32(6):491-6. doi: 10.1007/s00292-011-1479-2. German.
Results Reference
background
Links:
URL
http://www.worldlifeexpectancy.com/country-health-profile/madagascar
Description
Health Profile Madagascar. World Life Expectancy. Last time accessed: 15.01.2014
URL
http://www.hpvcentre.net/statistics/reports/XWX.pdf
Description
WHO/ICO. Information Centre on HPV and Cervical Cancer (HPV Information Centre) - Human Papillomavirus and Related Cancers in Madagascar. Summary Report 2010. 2010.

Learn more about this trial

Cervical Cancer Screening in Madagascar Using Smartphone Photos and Mobile Telemedicine

We'll reach out to this number within 24 hrs